The role of subclinical hypothyroidism in lipid metabolism disorders

Abstract

Subclinical hypothyroidism is common in general practice. The clinical significance of latent thyroid dysfunction has not yet been determined. The parameters of lipid metabolism and oxidative stress were studied in patients suffering from subclinical hypothyroidism between the ages of 18 and 50 years. They had a level of thyroid stimulating hormone ≥4 mIU/l, the level of free thyroxine was normal. The control group consisted of healthy individuals with thyroid-stimulating hormone level of 0,4–2,4 mIU/l. Thyroid status, thyroid peroxidase antibodies, lipid profile, malondialdehyde-modified low-density oxidized lipoproteins, antibodies to low-density oxidized lipoproteins, homocysteine were determined for all individuals. With the repeated determination of thyroid-stimulating hormone in 16,8% patients spontaneous recovery of thyroid-stimulating blood hormone level was observed, which was associated with lower values of thyroid-stimulating hormone and the absence of thyroid peroxidase antibodies. In the group of patients with thyroid stimulating hormone levels ≥7 mIU/l, the total cholesterol level was significantly (p=0,02) higher than in the control group. In patients with elevated values of malondialdehyde-modified oxidized low-density lipoprotein, thyroid stimulating hormone level of ≥7 mIU/l was more frequently detected. A negative correlation was found between the level of IgG antibodies to low-density oxidized lipoproteins and the concentration of free thyroxin. In the control group, the correlation was found between the concentration of IgG antibodies to low-density oxidized lipoproteins and the level of thyroid-stimulating hormone. In the group of subclinical hypothyroidism, the concentration of homocysteine was significantly (p=0,01) higher in men. In patients with subclinical hypothyroidism, more often hyperhomocysteinemia was detected compared with the control group. The results suggest that subclinical hypothyroidism is associated with initial changes in the metabolism of lipids and homocysteine.

Keywords

thyroid-stimulating hormone / lipid spectrum / total cholesterol / low-density lipoproteins / malondialdehyde- modified low-density lipoproteins / oxidized low-density lipoproteins IgG antibodies / homocysteine

References

[1] Белик, И.В. Содержание антител к модифицированным липопротеинам низкой плотности и их комплексов в крови пациентов с различными проявлениями атеросклероза / И.В. Белик [и др.] // Биомед. химия. – 2016. – № 4 (62). – C. 471–475.

[2] Волкова, А.Р. Субклинический гипотиреоз – новый фактор сердечно-сосудистого риска / А.Р. Волкова [и др.] // Терапия. – 2016. – № 6. – С. 23–28.

[3] Сабанов, В.И. Активность перекисного окисления липидов, антиоксидантной защиты и состояния миокарда при экспериментальном гипер- и гипотиреозе / В.И. Сабанов, И.Г. Джиоев, А.Т. Лолаева // Междунар. журн. прикл. и фунд. исслед. – 2017. – № 6. – C. 241–244.

[4] Фадеев, В.В. По материалам клинических рекомендаций Американской ассоциации клинических эндокринологов и Американской тиреоидной ассоциации по диагностике и лечению гипотиреоза у взрослых / В.В. Фадеев // Клин. и экспер. тиреоидология. – 2012. – № 3 (8). – C. 9–16.

[5] Bansal, S.K. A Study of the Extended Lipid Profile including Oxidized LDL, Small Dense LDL, Lipoprotein (a) and Apolipoproteins in the Assessment of Cardiovascular Risk in Hypothyroid Patients / S.K. Bansal, R. Yadav // Journal of Clinical and Diagnostic Research. – 2016. – № 6 (10). – C. 6–10.

[6] Baser, H. Assessment of oxidative status and its association with thyroid autoantibodies in patients with euthyroid autoimmune thyroiditis / H. Baser [et al.] // Endocrine. – 2015. – № 3 (48). – C. 916–923.

[7] Floriani, C. Subclinical thyroid dysfunction and cardiovascular diseases: 2016 update / C. Floriani [et al.] // European heart journal. – 2018. – № 39 (7). – С. 503–507.

[8] Hak, A.E. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study / A.E. Hak [et al.] // Annals of internal medicine. – 2000. – № 4 (132). – C. 270–278.

[9] Iseme, R.A. A role for autoantibodies in atherogenesis / R.A. Iseme [et al.] // Cardiovascular research. – 2017. – № 10 (113). – C. 1102–1112.

[10] Ittermann, T. Are serum TSH levels associated with oxidized low-density lipoprotein? Results from the Study of Health in Pomerania / T. Ittermann [et al.] // Clinical endocrinology. – 2012. – № 4 (76). – C. 526–532.

[11] Lee, M.W. The biochemical prognostic factors of subclinical hypothyroidism / M.W. Lee [et al.] // Endocrinology and metabolism (Seoul, Korea). – 2014. – № 2 (29). – C. 154–162.

[12] Pawlak, K. Oxidized LDL to autoantibodies against oxLDL ratio - the new biomarker associated with carotid atherosclerosis and cardiovascular complications in dialyzed patients / K. Pawlak, M. Mysliwiec, D. Pawlak // Atherosclerosis. – 2012. – № 1 (224). – C. 252–257.

[13] Suciu, C.F. Oxidized low-density lipoproteins: The bridge between atherosclerosis and autoimmunity. Possible implications in accelerated atherosclerosis and for immune intervention in autoimmune rheumatic disorders / C.F. Suciu [et al.] // Autoimmunity reviews. – 2018. – № 4 (17). – C. 366–375.

[14] Surks, M.I. Age-specific distribution of serum thyrotropin and antithyroid antibodies in the U.S. population: Implications for the prevalence of subclinical hypothyroidism / M.I. Surks, J.G. Hollowell // Journal of Clinical Endocrinology and Metabolism. – 2007. – № 12 (92). – C. 4575–4582.

RIGHTS & PERMISSIONS

Volkova A.R., Dygun O.D., Galkina O.V., Belyakova L.A., Bogdanova E.O.